Regenerative medicine company, Regeneus (ASX: RGS), announced today that Lonza, the world’s largest manufacturer of stem cells will manufacture Regeneus’ off-the-shelf cell therapy, CryoShot® Canine, for registration in the US. “It is very exciting to be partnering with Lonza, a global manufacturer with specialist experience in manufacturing stem cells to the quality standards that the US and European regulators require for product registration”, said Dr Duncan Thomson, Head of Veterinary Health at Regeneus. “We view this as the start of a long-term relationship in which Lonza will manufacture CryoShot for the world wide canine market. Our clinical trial work in Australia has been rewarding and it is now time to begin registration of the CryoShot product in the US and European markets.” The cells will be manufactured at the Lonza facility in Walkersville, Maryland and then distributed to the participating trial veterinarian clinics.
